The additional presentation is approved for the treatment of pediatric patients aged 6 to 17 years with plaque psoriasis or ...

The US FDA has approved GSK's 200 mg/ml autoinjector of Benlysta for individuals aged five years and above with active lupus ...

A subcutaneous injection is an injection into the fatty tissue. There are many types, ... Take deep breaths or encourage children to breathe deeply before the shot.

GSK’s approval expands belimumab treatment options, offering a first-of-its-kind subcutaneous option that can be administered ...

Intramuscular injections are absorbed faster than subcutaneous injections. ... The ventrogluteal muscle is the safest site for adults and children older than 7 months.

Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), in a ...

The US Food and Drug Administration (FDA) has approved the belimumab 200 mg/mL autoinjector for children aged 5 years of older with active lupus nephritis (LN) who are receiving standard therapy.

The approval of a new presentation enhances treatment flexibility for children with inflammatory diseases. In December 2024, ...

Incheon, South Korea Tuesday, June 17, 2025, 16:00 Hrs [IST] ...

PR Newswire LAS VEGAS, June 10, 2025 The growth hormone deficiency market is expected to see expansion across the 7MM driven by the introduction of innovative therapies, including ...

Belimumab is now the first and only subcutaneous biologic therapy approved for at-home administration in pediatric lupus nephritis.